CD4 count at presentation for HIV care in the United States and Canada: Are those over 50 years more likely to have a delayed presentation?
|
Article Reference |
|
Cohort profile: the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD)
|
Article Reference |
|
Competing risk regression models for epidemiologic data
|
Article Reference |
|
Effect of early versus deferred antiretroviral therapy for HIV on survival
|
Article Reference |
|
Evaluating competing adverse and beneficial outcomes using a mixture model
|
Article Reference |
|
Evaluation of human immunodeficiency virus biomarkers: inferences from interval and clinical cohort studies
|
Article Reference |
|
Identifying individuals with virologic failure after initiating effective antiretroviral therapy: The surprising value of mean corpuscular hemoglobin in a cross-sectional study
|
Article Reference |
|
Interval and clinical cohort studies: epidemiological issues
|
Article Reference |
|
Late presentation for human immunodeficiency virus care in the United States and Canada
|
Article Reference |
|
Trends in Multidrug Treatment Failure and Subsequent Mortality among Antiretroviral Therapy-Experienced Patients with HIV Infection in North America
|
Article Reference |
|
Trends in the incidence of cancers among HIV-infected persons and the impact of antiretroviral therapy: a 20-year cohort study
|
Article Reference |
|
Virologic and immunologic response to HAART, by age and regimen class
|
Article Reference |
|
When to start antiretroviral therapy
|
Article Reference |
|
Risk factors for tuberculosis after highly active antiretroviral therapy initiation in the United States and Canada: implications for tuberculosis screening.
|
Article Reference |
